Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Dynamic Changes in LH/FSH Ratios in Infants with Normal Sex Development

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Randomized Controlled Trial of Tesomet for Weight Loss in Hypothalamic Obesity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Increased liver fat associates with severe metabolic perturbations in low birth weight men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The Glucagon Receptor Antagonist LY2409021 has No Effect on Postprandial Glucose in Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Beta-hydroxybutyrate suppresses hepatic production of the ghrelin receptor antagonist, LEAP2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Type 2 diabetes is a common manifestation of metabolic dysfunction due to obesity and constitutes a major burden for modern health care systems, in concert with the alarming rise in obesity worldwide. In recent years, several successful pharmacotherapies improving glucose metabolism have emerged and some of these also promote weight loss, thus, ameliorating insulin resistance. However, the progressive nature of type 2 diabetes is not halted by these new anti-diabetic pharmacotherapies. Therefore, novel therapies promoting weight loss further and delaying diabetes progression are needed. Amylin, a beta cell hormone, has satiating properties and also delays gastric emptying and inhibits postprandial glucagon secretion with the net result of reducing postprandial glucose excursions. Amylin acts through the six amylin receptors, which share the core component with the calcitonin receptor. Calcitonin, derived from thyroid C cells, is best known for its role in humane calcium metabolism, where it inhibits osteoclasts and reduces circulating calcium. However, calcitonin, particularly of salmon origin, has also been shown to affect insulin sensitivity, reduce the gastric emptying rate and promote satiation. Preclinical trials with agents targeting the calcitonin receptor and the amylin receptors, show improvements in several parameters of glucose metabolism including insulin sensitivity and some of these agents are currently undergoing clinical trials. Here, we review the physiological and pharmacological effects of amylin and calcitonin and discuss the future potential of amylin and calcitonin-based treatments for patients with type 2 diabetes and obesity.

OriginalsprogEngelsk
Artikelnummer1261
TidsskriftEuropean Journal of Endocrinology
Vol/bind186
Udgave nummer6
Sider (fra-til)R93-R111
Antal sider19
ISSN0804-4643
DOI
StatusUdgivet - 21 apr. 2022

ID: 76296930